Expression of Matrix Metalloproteinase-7 Predicts Poor Prognosis in Gastric Cancer

Table 3

The association of MMP-7 status and clinicopathological outcome of gastric cancer.

Gastric mucosal pathology	MMP-7 status		OR; 95% CI	value
	Low expression ()	High expression ()
Location of tumor (%)
Upper	16 (13.67)	44 (15.54)	0.75 (0.61-0.92)	0.229
Middle	41 (35.04)	75 (26.50)	0.71 (0.54-0.93)	0.127
Lower	60 (51.28)	164 (57.95)	0.86 (0.71-1.14)	0.573
Tumor size (%)
<70 mm	68 (58.12)	153 (54.06)	0.67 (0.52-0.84)	0.872
≥70 mm	49 (41.88)	130 (45.93)	0.71 (0.64-0.92)	0.791
Histologic type (%)
Differentiated	82 (70.08)	94 (33.21)	0.96 (0.67-1.08)	0.092
Undifferentiated	35 (29.91)	189 (66.78)	2.89 (1.57-4.94)	0.018
Lymphatic invasion (%)
Absent	99 (84.61)	64 (22.61)	0.37 (0.14-0.76)	0.028
Present	18 (15.38)	219 (77.38)	9.87 (5.57-13.29)	0.019
Vascular invasion (%)
Absent	89 (76.06)	52 (18.37)	0.42 (0.21-0.83)	0.017
Present	28 (23.93)	231 (81.62)	8.16 (4.87-10.19)	0.015
Pathological TNM stage (%)
I	8 (6.83)	21 (7.42)	0.88 (0.69-0.97)	0.826
II	25 (21.36)	32 (11.30)	0.91 (0.88-1.19)	0.482
III	52 (44.44)	86 (30.38)	0.69(0.54-0.83)	0.257
IV	32(27.35)	144(50.88)	1.95 (1.04-3.08)	0.042
Residual tumor (%)	()	()
Microscopic	3 (33.33)	8 (36.36)	0.72 (0.54-0.93)	0.628
Gross (unresectable)	6 (66.66)	14 (63.63)	0.68 (0.41-0.84)	0.712
CEA (%)
<5.0 (ng/ml)	101 (86.32)	67 (23.67)	0.38 (0.19-0.69)	0.036
≥5.0 (ng/ml)	16 (13.67)	216 (76.32)	3.96 (1.68-5.27)	0.012

Univariate regression model analysis. considered as statistically significant.